Bile acid composition in fasting duodenal bile was assessed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized, doubleblind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a single bedtime dose. Specimens were analyzed
Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression
✍ Scribed by Claude Degott; Elie Serge Zafrani; Patrice Callard; Beverley Balkau; Renée Eug Poupon; Raoul Poupon
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 332 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The frequency with which florid duct lesions are seen in needle-biopsy specimens of the liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) versus placebo. Paired biopsy specimens o
There is no doubt that further investigations of this phenomenon will be performed and published promptly. Until these questions are answered, we may appreciate the accuracy of Ogden Nash's old observation that "While candy is dandy, liquor is quicker!" 1.
This placebo-controlled, randomized, multicenter trial compared the effects of MTX plus UDCA to UDCA alone on the course of primary biliary cirrhosis (PBC). Two hundred and sixty five AMA positive patients without ascites, variceal bleeding, or encephalopathy; a serum bilirubin less than 3 mg/dL; se
Induction of cytochrome P450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis. CYP3A is of key importance in human drug metabolism, being involved in presystemic extraction of more than 50% of all drugs currently available and of various endogenous